实施欧盟对抗微生物创新和获取的拉动激励措施:行动蓝图
Michael Anderson1, Adrian Towse2, Kevin Outterson3
1Health Organisation, Policy, Economics (HOPE), Centre for Primary Care & Health Services Research, The University of Manchester, Manchester, UK; LSE Health, Department of Health Policy, The London School of Economics and Political Science, London, UK.
欧盟正在制定一个新的吸引力激励措施,以鼓励抗微生物创新和获取. 关键考虑因素包括资金,设计和欧盟成员国之间的合作,以实现透明的实施.
科学领域:
- 制药政策 制药政策
- 传染病管理 传染病管理
- 公共卫生 公共卫生
背景情况:
- 欧盟理事会建议在2023年6月推出跨国拉动激励措施,以应对抗微生物创新和获取挑战.
- 抗菌素耐药性 (AMR) 需要新的策略来刺激新抗生素的开发.
研究的目的:
- 讨论实施欧盟拟议的抗微生物吸引激励措施的六个关键考虑因素.
- 为激励计划的设计,治理和成功采用提供建议.
主要方法:
- 这是一个个人观点的文章,介绍了政策建议的讨论和分析.
- 作者概述了在实施拉动激励措施时需要考虑的六个关键领域.
主要成果:
- 详细介绍了六个关键考虑因素:激励规模和成员国贡献,激励模式设计,与药物立法修订的整合,欧盟和成员国的角色,平衡拉动机制和全球合作.
- 自愿的成员国参与需要对抗微生物药物选择和获取协议的透明,包容和强有力的流程充满信心.
结论:
- 成功实施欧盟的拉动激励取决于解决概述的考虑因素.
- 确保透明度,包容性和方法严谨性对于成员国的参与和抗微生物创新战略的整体有效性至关重要.
更多相关视频
11:17Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
Published on: August 30, 2018
09:07Author Spotlight: Accelerating Diagnostic Accuracy with Direct Identification of Gram-Negatives from Blood Culture Bottles
Published on: May 24, 2024
相关概念视频
Antibiotic Selection
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Drug Control Governance: Regulatory Bodies and Their Impact
Antimicrobial Proteins
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...
Prescription, Nonprescription and Orphan Drugs
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
Healthcare Associated Infections II: Preventive Measures
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
